Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development
Rhea-AI Summary
Azenta's GENEWIZ division has formed a strategic partnership with Form Bio to enhance adeno-associated virus (AAV) gene therapy development. The collaboration integrates GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines to improve AAV gene therapy development workflows.
The partnership combines GENEWIZ's capabilities in synthesis, packaging of transgene expression cassettes, and long-read sequencing services with Form Bio's comprehensive AAV Genome Integrity Characterization using LAAVA software. This integration aims to streamline processes, reduce development time and costs, and provide better insights into AAV capsid contents for improved safety, efficacy, and manufacturability.
The partnership will be officially launched at the 27th Annual ASGCT Meeting in May 2025, where both companies will present their collaborative research.
Positive
- Integration of AI and sequencing technology could reduce time and costs in gene therapy development
- Partnership enhances AAV vector safety and efficacy analysis capabilities
- Streamlined workflow integration may accelerate path to market for gene therapies
Negative
- None.
News Market Reaction – AZTA
On the day this news was published, AZTA declined 3.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy with Form Bio's AI- and machine learning-powered analysis pipelines. The integration of these capabilities aims to provide gene therapy developers with data-driven insights into AAV capsid contents, improving safety, efficacy, and manufacturability.
GENEWIZ will provide synthesis and packaging of transgene expression cassettes, complemented by high-quality, long-read sequencing services for AAV gene therapy. Form Bio will conduct comprehensive AAV Genome Integrity Characterization using Long-read AAV Analysis (LAAVA) software, identifying key opportunities to enhance vector integrity and safety, while providing actionable insights through detailed reporting. This combination enables a streamlined process that integrates sequencing, vector design, and development workflows, ultimately reducing time and cost to reach lead candidates, accelerating the path to market for innovative therapies.
"Our collaboration with Form Bio marks a major step forward in simplifying AAV gene therapy workflows," said Ginger Zhou, President at GENEWIZ. "By combining our sequencing expertise with their cutting-edge analysis, we are enabling researchers to make more informed decisions and break through traditional hurdles found in gene therapy development."
"Partnering with GENEWIZ allows us to embed our genome integrity insights directly into sequencing workflows," said Andrew Busey, Co-Founder and CEO at Form Bio. "By integrating analysis earlier in the process, we're helping gene therapy developers accelerate timelines, enhance vector safety, and improve the likelihood for clinical success."
The partnership will officially launch at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2025, where both companies will be exhibiting (booth numbers 1711 and 1143). A poster highlighting their collaborative work "The Long and Short of It: Comparing Next Generation Sequencing Methods for Quality Control in AAV Development" will be presented on May 15, 5:30-7:00 pm EST, poster #1612.
About Form Bio
Form Bio delivers cutting-edge AI and computational solutions to accelerate therapeutic development in cell and gene therapy. With its proprietary FORMsightAI platform, Form Bio enables rapid in silico genome integrity characterization and optimization of nucleic acid-based therapies—streamlining lead candidate selection. By integrating AI-powered design with deep expertise in molecular biology, bioinformatics, software engineering, and data science, Form Bio empowers drug developers to enhance therapeutic safety, efficacy, and manufacturability while reducing time and costs.
Form Bio is headquartered in
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-and-form-bio-announce-strategic-partnership-to-advance-aav-gene-therapy-development-302454449.html
SOURCE Azenta, Inc.
FAQ
What is the strategic partnership between Azenta (AZTA) and Form Bio?
How will the Azenta-Form Bio partnership improve gene therapy development?
What specific technologies are being combined in the AZTA-Form Bio collaboration?
When will Azenta and Form Bio launch their partnership officially?
